Features of aldosterone antagonists in the treatment of patients with acute myocardial infarction with ST elevation without chronic heart failure and post-MI chronic heart failure with low ejection fraction

Abstract

Aim. In order to study the possibilities of aldosterone antagonists in the treatment of patients with acute myocardial infarction with ST elevation without chronic heart failure and post-MI chronic heart failure with low ejection fraction recent researches on this problem were reviewed. The literature data and the results of multicenter randomized controlled trials (RCTs), which will expand not only the understanding of the mechanisms of action of aldosterone receptor antagonists, but also new areas of their application in clinical practice, were analyzed. Conclusions. Randomized studies have shown that the efficiency of the selective aldosterone antagonist eplerenone has advantages over spironolactone in the improvement of prognosis in post-MI patients with LV systolic dysfunction and/or clinical signs of heart failure.

Keywords

• Myocardial Infarction
• Acute Disease
• Randomized Controlled Trials as Topic
• Aldosterone